← Russell 3000 cross-section

TECH BIO-TECHNE Corp

Trailing twelve months to 2026-06-30 · as filed 2026-08-24, not restated
Healthcare

Scale

Market cap
$11.3bn
Revenue TTM
$1.2bn
Net income TTM
$182m
Free cash flow
$263m
Composite score
45.9
Sector rank
#660

Valuation

P / E
62.1
EV / EBITDA
31.6
EV / sales
9.1
FCF yield
2.33%
Earnings yield vs 10-yr
-3.12pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
15.0%
EBITDA margin
28.7%
ROE
8.6%
ROIC
13.7%
Revenue growth
-0.4%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

RESULTS OF OPERATIONS Net Sales Consolidated net sales for the quarter ended March 31, 2026 decreased 2% to $311.4 million compared to the same prior year period. Consolidated net sales for the nine months ended March 31, 2026 were $893.8 million, a decrease of 1% from the same prior year period. Organic revenue for the quarter ended March 31, 2026 decreased 2% compared to the prior year. Foreign currency exchange had a favorable impact of 2% and non-recurring prior year revenue from a business held-for-sale had an unfavorable impact of 2%. Organic revenue for the nine months ended March 31, 2026 decreased 1% compared to the prior year. …BIO-TECHNE Corp, 10-Q, period ended 2026-03-31, filed 2026-05-06

Read the full passage →